Patents by Inventor Hiromi Nonaka
Hiromi Nonaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080039337Abstract: This invention provides a method for detection of conformational change of a protein immobilized on a substrate. In concrete, the method comprises, forming a sample film comprising a protein immobilized on a substrate, adding a substance to be detected for its activity to affect to the conformational change of the protein onto the sample film, and detecting the conformational change of the protein. The method enables to measure conformational change of a protein with immobilized state, using minute amount of protein in a short period for a number of samples in a short period all at once, rapidly and simply.Type: ApplicationFiled: September 21, 2005Publication date: February 14, 2008Applicant: FUENCE CO., LTD.Inventors: Hiromi Nonaka, Hiroshi Kase, Kozo Inoue
-
Publication number: 20080003691Abstract: The inventors investigated to provide a means for real-time detection and measurement on the process of the amyloid protein aggregation as change(s) in tension and/or elasticity using a force sensor. The present invention provided a method of detecting an amyloidgenic conformational change of a protein using a mechanochemical sensor. The present invention further provided a method of searching a substance having an activity that affects to an amyloidgenic conformational change using said detecting method, as well as a method of searching a therapeutic or diagnostic agent for amyloid-related diseases. The method of the present invention is assumed to contribute to obtain a novel therapeutic or diagnostic agent for amyloid diseases.Type: ApplicationFiled: March 24, 2005Publication date: January 3, 2008Applicant: Fuence Co., Ltd.Inventors: Masayoshi Tachibana, Machiko Tachibana, Hiromi Nonaka, Hiroshi Kase
-
Publication number: 20070202258Abstract: There is provided a micro-pattern forming apparatus including an electrospraying part for applying a voltage to a solution containing a sample to electrostatically atomizing the solution; a supporting part (30) for supporting a chip (26), on which the sample in the solution electrostatically atomized by the electrospraying part, is to be deposited; and a fine mask part (24) disposed between the electrospraying part and the supporting part, having a mask pattern for being passed through by the electrostatically atomized solution in order to form a micro-pattern of the sample upon the chip, wherein the mask pattern is made from a photoresist material with concavity and convexity on the side of the supporting part.Type: ApplicationFiled: August 30, 2006Publication date: August 30, 2007Applicants: FUENCE CO., LTD., RIKENInventors: Yutaka Yamagata, Hitoshi Ohmori, Hiroshi Kase, Hiromi Nonaka, Ai Kaneko, Kazuya Nitta
-
Publication number: 20060252679Abstract: The present invention provides an agent for prevention and/or treatment of itching comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R1 represents substituted or unsubstituted lower alkyl, etc.; R2 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; R3 and R4 are the same or different and each represents hydrogen, lower alkyl, etc.; n represents 0 or 1; X represents —(CH2)2—, etc.; and Y represents the formula (II); (wherein W represents CH or a nitrogen atom; Z1 and Z2 are the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, etc.; and Z3 represents hydrogen, substituted or unsubstituted lower alkyl, etc.Type: ApplicationFiled: August 22, 2003Publication date: November 9, 2006Inventors: Mayumi Saki, Hiromi Nonaka, Hiromasa Miyaji, Shunji Ichikawa, Chiemi Takashima, Tsutomu Matsumura, Hitoshi Arai, Katsutoshi Sasaki, Choei Kobatake, Yukihito Tsukumo, Kyoichiro Iida, Takeshi Kuboyama, Haruhiko Manabe
-
Publication number: 20060239999Abstract: The present invention provides an agent for prevention and/or treatment of asthma comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient.Type: ApplicationFiled: August 22, 2003Publication date: October 26, 2006Inventors: Mayumi Saki, Hiromi Nonaka, Hiromasa Miyaji, Naoko Hiura, Haruhiko Manabe, Tsotomu Matsumura, Hitoshi Arai, Katsutoshi Sasaki, Cjoei Kobatake, Kyoichiro Iida, Takeshi Kuboyama
-
Publication number: 20040110826Abstract: The present invention provides an &agr;2c-adrenoceptor antagonist comprising, as an active ingredient, a condensed-ring-pyrimidine derivative represented by general formula (I) below or a pharmaceutically acceptable salt thereof useful for treating and/or preventing various diseases induced by hyperactivity of &agr;2c-adrenoceptor (for example, Parkinson's disease, L-DOPA-induced dyskinesia, tardive dyskinesia and depression) and the like.Type: ApplicationFiled: May 28, 2003Publication date: June 10, 2004Inventors: Noriaki Uesaka, Hironori Imma, Hajime Kashima, Masako Kurokawa, Hiromi Nonaka, Tomoyuki Kanda, Yoshihisa Kuwana, Shinichiro Toki, Junichi Shimada
-
Patent number: 6306847Abstract: The present invention provides condensed purine derivatives or pharmacologically acceptable salts thereof exhibiting adenosine A3 acceptor antagonising activity, and having an antiasthmatic action, a bronchodilator action, an antiantiitching action, etc., and represented by the following formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents hydrogen, lower alkyl, alicyclic alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents hydrogen, lower alkyl, or substituted or unsubstituted aralkyl; X1 and X2 are the same or different and each represents hydrogen, lower alkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aryl; and n represents an integer of 0 to 3).Type: GrantFiled: June 5, 1998Date of Patent: October 23, 2001Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hiroshi Tsumuki, Mayumi Saki, Hiromi Nonaka, Michio Ichimura, Junichi Shimada, Fumio Suzuki, Shunji Ichikawa, Nobuo Kosaka
-
Patent number: 6222035Abstract: [1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A2A receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A2A receptors (for example, Parkinson's disease or senile dementia): wherein R1 represents substituted or unsubstituted aryl, or the like; R2 represents hydrogen, halogen, lower alkyl, substituted or unsubstituted aryl, or the like; R3 represents hydrogen, halogen, XR10 (wherein X represents O or S; and R10 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aralkyl, lower alkyl, or hydroxy lower alkyl), or the like; and Q represents hydrogen or 3,4-dimethoxybenzyl.Type: GrantFiled: September 23, 1999Date of Patent: April 24, 2001Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hiroshi Tsumuki, Junichi Shimada, Hironori Imma, Akiko Nakamura, Hiromi Nonaka, Shizuo Shiozaki, Shunji Ichikawa, Tomoyuki Kanda, Yoshihisa Kuwana, Michio Ichimura, Fumio Suzuki
-
Patent number: 6107064Abstract: The present invention relates to a process for producing a xanthine derivative represented by formula (II), comprising converting a xanthine derivative represented by formula (I) {hereinafter, referred to as Compound (I)}: ##STR1## (wherein R.sup.1 and R.sup.2 independently represent hydrogen, or hydroxy-substituted, oxo-substituted, or unsubstituted lower alkyl) into a xanthine derivative represented by formula (II) {hereinafter, referred to as Compound (II)}: ##STR2## (wherein R.sup.3 and R.sup.4 independently represent hydrogen, or hydroxy-substituted, oxo-substituted, or unsubstituted lower alkyl; R.sup.5 and R.sup.6 independently represent hydrogen, hydroxy, or oxo; with the proviso that R.sup.5 and R.sup.6 are both hydrogen, at least one of R.sup.3 and R.sup.Type: GrantFiled: January 17, 1996Date of Patent: August 22, 2000Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Junichi Shimada, Tamotsu Eguchi, Kenichi Mochida, Akira Horiguchi, Tohru Yasuzawa, Hideaki Kusaka, Hiromi Nonaka, Fumio Suzuki
-
Patent number: 5948784Abstract: Disclosed are quinazoline derivatives represented by formula (I): wherein R.sup.1 represents hydrogen, lower alkyl, alkenyl, or aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 represent hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, or the like; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 represent hydrogen, lower alkyl, lower alkoxy, aralkyloxy, or the like, or any adjoining two of them are combined to form methylenedioxy or the like; R.sup.10 represents hydrogen, lower alkyl, or the like; R.sup.11 and R.sup.12 represent hydrogen, lower alkyl, cycloalkyl, phenyl, or aralkyl, or R.sup.11 and R.sup.12 are combined together with N to form a heterocyclic group; and n represents 0, 1 or 2, and pharmaceutically acceptable salts thereof. These compounds have adenosine uptake inhibitory activity and are useful for the protection of myocardium and for the prevention or treatment of renal diseases such as nephritis and diabetic nephropathy.Type: GrantFiled: June 3, 1998Date of Patent: September 7, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shigeki Fujiwara, Yuko Okamura, Haruki Takai, Hiromi Nonaka, Takahiro Moriyama, Kozo Yao, Akira Karasawa
-
Patent number: 5756735Abstract: The present invention relates to novel xanthine derivatives of the formula (I) which are selectively antagonistic to an adenosine A.sub.2 receptor, and pharmaceutically acceptable salts thereof. Formula (I): ##STR1## In the formula, R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom, a propyl group, a butyl group or an allyl group; R.sup.3 represents a hydrogen atom or a lower alkyl group; Y.sup.1 and Y.sup.2 are the same or different and each represents a hydrogen atom or a methyl group; and Z represents a substituted or unsubstituted phenyl group, a pyridyl group, an imidazolyl group, a furyl group or a thienyl group.Type: GrantFiled: June 7, 1995Date of Patent: May 26, 1998Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Fumio Suzuki, Akio Ishii, Hiromi Nonaka, Nobuo Kosaka, Shunji Ichikawa, Junichi Shimada
-
Patent number: 5703085Abstract: The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl, R.sup.4 represents lower alkyl, or substituted or unsubstituted aryl, R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl, and lower alkoxy, or R.sup.5 and R.sup.6 are combined together to represent --O--(CH.sub.2)p--O-- (p is an integer of 1 to 3), n represents 0, 1, or 2, and m represents 1 or 2.The compounds of the present invention have an adenosine A.sub.2 receptor antagonistic activity, and are useful for the treatment or prevention of various kinds of diseases caused by hyperergasia of adenosine A.sub.2 receptors (for example, Parkinson's disease, senile dementia, depression, asthma, and osteoporosis).Type: GrantFiled: October 20, 1995Date of Patent: December 30, 1997Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Fumio Suzuki, Nobuaki Koike, Junichi Shimada, Joji Nakamura, Shizuo Shiozaki, Shigeto Kitamura, Shunji Ichikawa, Hiroshi Kase, Hiromi Nonaka
-
Patent number: 5670498Abstract: Disclosed are xanthine derivatives represented by the following Formula (I): ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen or lower alkyl;Q.sup.1, Q.sup.2, and Q.sup.3 independently represent hydrogen, lower alkyl, lower alkoxy, or halogen;and X represents --COR.sup.4 (in which R.sup.4 represents hydrogen, hydroxy, lower alkyl, or lower alkoxy) or --SO.sub.2 R.sub.5 {in which R.sup.5 represents hydroxy, lower alkoxy, trifluoromethyl, ##STR2## in which R.sup.6 and R.sup.7 independently represent hydrogen, hydroxy-substituted or unsubstituted lower alkyl, aryl, or ##STR3## (in which m represents an integer of 1 to 3; and R.sup.8 and R.sup.9 independently represent hydrogen or lower alkyl), or ##STR4## (in which Y represents a single bond, oxygen, or N--R.sup.10 in which R.sup.10 represents hydrogen or lower alkyl; and n1 and n2 independently represent an integer of 1 to 3)}, and pharmaceutically acceptable salts thereof.Type: GrantFiled: September 13, 1995Date of Patent: September 23, 1997Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Fumio Suzuki, Junichi Shimada, Nobuaki Koike, Hiroshi Kase, Joji Nakamura, Shizuo Shiozaki, Hiromi Nonaka
-
Patent number: 5658917Abstract: The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.Type: GrantFiled: April 28, 1995Date of Patent: August 19, 1997Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shigeki Fujiwara, Daisuke Machii, Haruki Takai, Hiromi Nonaka, Hiroshi Kase, Kozo Yao, Michiyo Kawakage, Hideaki Kusaka, Akira Karasawa
-
Patent number: 5648353Abstract: The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.Type: GrantFiled: May 22, 1995Date of Patent: July 15, 1997Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shigeki Fujiwara, Daisuke Machii, Haruki Takai, Hiromi Nonaka, Hiroshi Kase, Kozo Yao, Michiyo Kawakage, Hideaki Kusaka, Akira Karasawa
-
Patent number: 5624926Abstract: The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.Type: GrantFiled: October 17, 1994Date of Patent: April 29, 1997Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shigeki Fujiwara, Daisuke Machii, Haruki Takai, Hiromi Nonaka, Hiroshi Kase, Kozo Yao, Michiyo Kawakage, Hideaki Kusaka, Akira Karasawa
-
Patent number: 5605900Abstract: The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C-R.sup.11 (wherein R.Type: GrantFiled: April 28, 1995Date of Patent: February 25, 1997Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shigeki Fujiwara, Daisuke Machii, Haruki Takai, Hiromi Nonaka, Hiroshi Kase, Kozo Yao, Michiyo Kawakage, Hideaki Kusaka, Akira Karasawa
-
Patent number: 5587378Abstract: Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 is cycloalkyl, --(CH.sub.2).sub.n --R.sup.5, wherein R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R.sup.6 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 are independently O or S.Type: GrantFiled: May 23, 1995Date of Patent: December 24, 1996Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Fumio Suzuki, Junichi Shimada, Nobuaki Koike, Joji Nakamura, Shizuo Shiozaki, Shunji Ichikawa, Akio Ishii, Hiromi Nonaka
-
Patent number: 5525607Abstract: Novel xanthine compounds represented by the following formula: ##STR1## wherein each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents: ##STR2## The compounds are useful as a diuretic, a renal-protecting agent and bronchodilator.Type: GrantFiled: May 20, 1993Date of Patent: June 11, 1996Assignee: Kyowa Hakko Kogyo Co., LtdInventors: Fumio Suzuki, Junichi Shimada, Akio Ishii, Tetsuji Ohno, Akira Karasawa, Kazuhiro Kubo, Hiromi Nonaka, Fumio Suzuki, Junichi Shimada, Akio Ishii, Tetsuji Ohno, Akira Karasawa, Kazuhiro Kubo, Hiromi Nonaka
-
Patent number: 5484920Abstract: Agents for the treatment of Parkinson's disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## in which R.sup.1, R.sup.2 are R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 represent independently O or S.Type: GrantFiled: October 7, 1993Date of Patent: January 16, 1996Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Fumio Suzuki, Junichi Shimada, Nobuaki Koike, Joji Nakamura, Shizuo Shioazaki, Shunji Ichikawa, Akio Ishii, Hiromi Nonaka